Incyte Corporation research snapshot
INCY AI stock analysis currently reads Incyte Corporation as a profitable specialty biopharma company with a net-cash balance sheet, durable Jakafi cash flow, faster growth from Opzelura and the hematology and oncology portfolio, and a deep late-stage pipeline. At the August 2, 2026 data cutoff, INCY traded near $119.52 after the July 31 close with a verified market value near $24.23 billion. The stock is in a constructive uptrend above its 50-day and 200-day moving averages, but near-term reported earnings are distorted by a one-time $246 million CMS settlement benefit in Opzelura net sales and by a roughly $1.25 billion Vega in-process research and development charge that will hit the third quarter of 2026. The AI stock forecast remains scenario-based because future value depends on Jakafi durability, Opzelura and povorcitinib adoption, late-stage clinical execution, regulatory timing, and whether the Vega acquisition returns its $1.25 billion upfront cost. This page is informational research, not investment advice.
Current price
$119.52
Market cap
$24.23 billion verified market cap
AI score
68 / 100
Rating
Profitable specialty biopharma with a net-cash balance sheet, strong non-Jakafi growth, and one-time CMS and Vega charges that distort near-term earnings
Trend status
Constructive uptrend above the 50-day and 200-day moving averages with cooling momentum after a post-earnings pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Incyte sells approved medicines in hematology, oncology, and inflammation with gross margins above 90%, strong free cash flow, and Q2 2026 total revenue growth of 38%. | High |
| Moat | The moat comes from approved indications, clinical evidence, prescriber familiarity, reimbursement access, manufacturing quality, and know-how in JAK biology, but it is narrower than a diversified large pharma moat and depends on patent exclusivity. | Medium |
| Management | CEO Bill Meury, in place since June 2025, brings commercial and deal experience, and the board uses equity ownership guidelines, but the next test is whether Vega and late-stage pipeline spending earn returns above their cost. | Medium |
| Financial trend | FY2025 revenue rose 21% to $5.14 billion, TTM revenue reached $5.82 billion, and Q2 2026 total revenue rose 38% to $1.67 billion with net income of $586 million. | High |
| Valuation | At $119.52, audited math shows about 15.2x TTM EPS, 12.6x TTM free cash flow per share, 3.8x book value, and a 7.9% free cash flow yield, while the forward P/E is inflated by the expected Vega charge. | Medium-high |
| Technical trend | The stock traded above the 50-day and 200-day moving averages with RSI near 55, which is positive but less extended than earlier in the year. | Medium |
| Risk level | Key risks are Jakafi concentration, patent and pricing pressure, Opzelura growth expectations, clinical trial setbacks, FDA timing, and whether the $1.25 billion Vega upfront cost converts into an approved product. | Medium-high |
| AI confidence | Descriptive confidence is high because the public data set is rich. Forecast confidence is medium because drug-specific events and one-time items can reset sales expectations and multiples. | High data confidence |
| Investment certainty | Investment certainty is medium. The balance sheet and cash flow are strong, but the current price already discounts a meaningful amount of pipeline and launch success, and near-term earnings include one-time distortions. | Medium |
INCY AI stock forecast
The INCY AI stock forecast uses scenario math around the $119.52 cutoff price and TTM EPS of $7.85. The audited three-year model produced valuation anchors near $188 in the bullish case, $124 in the base case, and $63 in the bearish case. These ranges are not price promises. They are a way to frame what must happen for upside, base, or downside outcomes to become more likely, and they should be read with the caveat that 2026 reported earnings include a one-time $246 million CMS benefit and a roughly $1.25 billion Vega charge.
$160 to $190
More likely if Jakafi and Jakafi XR stay durable, Opzelura keeps double-digit demand growth, povorcitinib and Opzelura regulatory decisions land on time, tafasitamab launches in first-line DLBCL, latarcibart keeps credible late-stage value, the Vega charge is treated as a one-time cost, and investors pay a mid-teens multiple on normalized earnings.
$115 to $130
More likely if revenue grows at a mid-single-digit to high-single-digit rate, R&D spend stays heavy but productive, Opzelura and the hematology and oncology portfolio offset slower Jakafi growth, and the market values Incyte near its 1-year average analyst price target of about $123.
$60 to $75
More likely if Jakafi erosion arrives faster than expected, Opzelura underperforms after the one-time CMS benefit, FDA or trial events disappoint, povorcitinib or latarcibart fail to convert, the Vega acquisition creates a large charge without commercial confidence, or the multiple compresses toward single digits.
INCY AI technical analysis
INCY AI technical analysis is constructive but needs live confirmation after a post-earnings pullback. As of the August 2, 2026 cutoff, StockAnalysis listed INCY at $119.52 after the July 31 close, with the 50-day moving average at $109.13, the 200-day moving average at $101.26, RSI at 55.17, and average 20-day volume near 1.91 million shares. Investing.com could not be reached at this refresh, so the technical picture relies on StockAnalysis plus analyst price targets, and live chart confirmation is required before acting on any level.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $119.52 | StockAnalysis quote snapshot after the July 31, 2026 close, used for market-cap and valuation math. |
| Near support | $109 to $115 | StockAnalysis listed the 50-day moving average at $109.13, making this the first trend reference after the post-earnings pullback. |
| Secondary support | $101 to $105 | StockAnalysis listed the 200-day moving average at $101.26. A move toward this zone would be a larger technical reset. |
| Long-term trend reference | $101 | The 200-day moving average is the main long-term trend line, and the stock has held well above it during the 52-week rally. |
| Resistance | $120 to $125 | S&P Global lists a median analyst price target near $120 and an average target of $122.96. A clean breakout needs volume support and no negative product, FDA, or clinical news. |
| Momentum | RSI 55.17 | RSI sits above 50 but well below the overbought zone, so momentum is positive but less stretched than earlier in the year. The 52-week price change is about +54%. |
| Volume | 1.91 million average 20-day shares | Volume should be interpreted around earnings, FDA decisions, trial data, patent news, and Vega or pipeline updates. |
| Volatility | Beta 0.76, event-sensitive biotech risk | StockAnalysis listed beta below one, but biopharma-specific events such as FDA decisions and trial data can still create large single-stock moves. |
| Invalidation | Close below $109, then below $101 | A break below the 50-day moving average would weaken swing momentum. A sustained break below the 200-day moving average would require a fuller thesis review. |
INCY AI trading strategy
The INCY AI trading strategy below is a rules-based framework for a profitable biopharma stock with net cash, product concentration, and regulatory or clinical catalysts. It is not personal advice and should be paired with live quotes, filings, FDA calendars, position sizing, and risk controls.
Watch for INCY to hold above the $109 to $115 area and break cleanly above $120 to $125 with confirming volume, stable Jakafi commentary, and no negative Opzelura, FDA, trial, or Vega news.
A close below $109 should reduce swing confidence. A close below the $101 to $105 area should trigger a full review of both chart momentum and the fundamental setup.
If INCY pulls back toward the $101 to $105 area without a new product, patent, clinical, or guidance problem, compare the reset price with normalized TTM EPS, free cash flow yield, net cash per share, and the audited base scenario.
Do not treat every pullback as a bargain. Product-specific bad news or the one-time Vega charge can turn a technical reset into a fundamental break.
Track Jakafi and Jakafi XR paid demand, Opzelura prescription demand, Niktimvo uptake, Monjuvi and Zynyz progress, povorcitinib regulatory milestones, latarcibart trial progress, R&D intensity, cash balance, and how the Vega acquisition is accounted for and integrated.
Lower confidence if earnings growth depends mainly on multiple expansion or one-time items rather than durable product growth and pipeline conversion.
Investment research summary
Incyte converts drug discovery, clinical development, regulatory approvals, and specialty commercial execution into recurring medicine revenue for serious hematology, oncology, and inflammatory diseases.
The moat is based on approved labels, physician trust, payer access, clinical data, manufacturing quality, and know-how in JAK biology and hematology. It weakens if exclusivity fades, rivals show better efficacy or safety, or payers force price concessions.
The thesis fails if Jakafi concentration proves larger than new product growth, Opzelura misses adoption expectations after the one-time CMS benefit, late-stage programs disappoint, regulatory decisions slip, or the Vega acquisition consumes $1.25 billion of cash without creating durable earnings power.
Bill Meury joined as CEO in June 2025 with commercial and deal experience. The board has equity ownership guidelines of 6x annual base salary for the CEO and a clawback policy, but capital allocation should be judged by pipeline returns, launch execution, cash discipline, and whether the Vega transaction expands the hematology moat.
Specialty biopharma benefits from aging populations, immunology demand, hematology innovation, targeted oncology, and rare disease development. The same industry faces patent cliffs, payer pressure, trial failure, FDA timing, and policy scrutiny.
INCY trades at about 15.2x TTM EPS, 12.6x free cash flow, and a 7.9% free cash flow yield, which looks reasonable, but the forward P/E is inflated by the expected Vega charge. Margin of safety depends on whether free cash flow stays durable, the pipeline converts into approved products, and the market separates one-time charges from normalized earnings.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| INCY quote reference | $119.52 close on July 31, 2026 | StockAnalysis INCY statistics | August 2, 2026 |
| Market capitalization verification | $24.23 billion, verified as $119.52 x about 202.70 million shares | Pineify financial_rigor.py and StockAnalysis share data | August 2, 2026 |
| Shares outstanding | 202.70 million shares outstanding | StockAnalysis INCY statistics | August 2, 2026 |
| FY2025 revenue | $5.14 billion total revenue, up 21% compared with fiscal 2024 | Incyte FY2025 Form 10-K | August 2, 2026 |
| Q2 2026 total revenue and net sales | $1.67 billion total revenue and $1.49 billion total net sales, up 38% and 40% | Incyte Q2 2026 Form 10-Q | August 2, 2026 |
| Q2 2026 product mix | Jakafi $816.7 million, Opzelura $449.7 million including a $246.0 million one-time CMS settlement benefit, other hematology and oncology $221.7 million | Incyte Q2 2026 Form 10-Q | August 2, 2026 |
| TTM financials | TTM revenue $5.82 billion, net income $1.61 billion, diluted EPS $7.85, operating cash flow $1.98 billion, free cash flow $1.92 billion | StockAnalysis INCY financials | August 2, 2026 |
| Cash and net cash | Cash and marketable securities $4.54 billion and net cash $4.50 billion at June 30, 2026, about $21.93 to $22.19 per share | StockAnalysis INCY balance sheet | August 2, 2026 |
| Debt and credit facility | $38.27 million total debt and a $500 million undrawn revolving credit facility maturing in June 2027 | Incyte Q2 2026 Form 10-Q and StockAnalysis statistics | August 2, 2026 |
| Vega acquisition | $1.25 billion upfront acquisition of Vega Therapeutics completed July 6, 2026, plus up to $750 million in sales milestones, with the upfront expensed in R&D during the third quarter of 2026 | Incyte Q2 2026 Form 10-Q Note 17 | August 2, 2026 |
| TTM valuation math | 15.23x P/E, 3.79x price-to-book, 12.62x P/FCF, and 7.92% FCF yield from financial_rigor.py | Pineify financial_rigor.py using StockAnalysis inputs | August 2, 2026 |
| Technical snapshot | 50-day moving average $109.13, 200-day moving average $101.26, RSI 55.17, beta 0.76, average 20-day volume 1.91 million shares | StockAnalysis INCY statistics | August 2, 2026 |
| Analyst consensus | Buy rating from 27 analysts, average 1-year price target $122.96, low $86, high $150 | StockAnalysis INCY forecast via S&P Global | July 30, 2026 |
| Management and incentives | CEO Bill Meury joined in June 2025, and the 2026 proxy lists CEO equity ownership guidelines at 6x annual base salary | Incyte 2026 proxy statement | August 2, 2026 |
This INCY AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of August 2, 2026 and can be wrong if earnings, clinical data, regulatory decisions, payer policy, patent events, market multiples, or company execution change. Reported earnings include a one-time $246 million CMS settlement benefit and an expected Vega in-process research and development charge.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
